Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
dinaciclib (MK-7965)
i
Other names:
MK-7965, SCH 727965, MK 7965, SCHOOL 727965, PS-095760, SCH-727965, NSC 747135
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
Ligand, Merck (MSD)
Drug class:
CDK inhibitor
Related drugs:
‹
SNS-032 (4)
PHA 793887 (1)
AT7519 (0)
R-547 (0)
RGB-286638 (0)
E7070 (0)
P27600 (0)
BAY1000394 (0)
SNS-032 (4)
PHA 793887 (1)
AT7519 (0)
R-547 (0)
RGB-286638 (0)
E7070 (0)
P27600 (0)
BAY1000394 (0)
›
Associations
(4)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors (NCT01434316)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
02/04/2025
Initiation :
11/11/2011
Primary completion :
03/28/2023
Completion :
08/02/2025
BRCA1 • BRCA2 • BRCA • RAD51
|
BRCA mutation
|
veliparib (ABT-888) • dinaciclib (MK-7965)
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer (NCI-2018-01053) (NCT01676753)
Phase 1b
Jo Chien
Jo Chien
Completed
Phase 1b
Jo Chien
Completed
Last update posted :
09/21/2022
Initiation :
12/28/2016
Primary completion :
06/30/2020
Completion :
02/28/2022
PGR
|
PGR expression
|
Keytruda (pembrolizumab) • dinaciclib (MK-7965)
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer (NCT01624441)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
03/30/2018
Initiation :
08/21/2012
Primary completion :
09/10/2013
Completion :
09/10/2013
HER-2 • ER • PGR • MCL1
|
HER-2 amplification • HER-2 negative
|
epirubicin • dinaciclib (MK-7965)
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) (NCT00732810)
Phase 2
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Completed
Phase 2
Merck Sharp & Dohme LLC
Completed
Last update posted :
08/05/2015
Initiation :
07/01/2008
Primary completion :
06/01/2011
Completion :
06/01/2011
HER-2
|
HER-2 positive
|
erlotinib • capecitabine • dinaciclib (MK-7965)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login